Original Article
Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis of 13 studies
Abstract
Background: The characteristic and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema (CPFE) have long been assessed, but results were controversial. Therefore, we performed a meta-analysis to assess the clinical features and prognosis of lung cancer patients with CPFE.
Methods: The databases PubMed, Embase, and Web of Science (updated to October 1, 2017) were searched for eligible studies. Pooled odds ratios (ORs), weighted mean differences (WMD) or hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to evaluate the clinicopathological characteristics, the short-term outcome after operation and long-term survival of lung cancer patients with CPFE compared with lung cancer patients without CPFE (fibrosis, emphysema, and normal).
Results: Thirty original studies with 8,050 patients were included in this meta-analysis. The pooled results indicated that lung cancer patients with CPFE were associated with higher age (MD =3.39; 95% CI: 2.12–4.67, P<0.001), male (OR =8.46; 95% CI: 6.36–11.26, P<0.001), ex- or current smoker (OR =39.65; 95% CI: 15.64–100.5, P<0.001), longer smoking history (MD =15.56; 95% CI: 3.73–27.39, P=0.01), lower DLCO% (MD =−13.82; 95% CI: −21.4 to −6.24, P<0.001), squamous cell carcinoma histology (OR =3.55; 95% CI: 2.49-5.05, P<0.001), the lower lobes (OR =1.92; 95% CI: 1.52–2.43, P<0.001), advanced pathological stage (OR =1.55; 95% CI: 1.22–1.96, P<0.001). Lung cancer patients with CPFE had higher 30-day mortality (OR =4.72, 95% CI: 2.06–10.85, P<0.001), 90-day mortality (OR =5.33; 95% CI: 1.39–20.42, P=0.01), and incidence of postoperative complications (OR =5.25, 95% CI: 2.38–11.57, P<0.001). In addition, the lung cancer patients with CPFE had a poorer OS (HR =2.006, 95% CI: 1.347–2.986, P=0.001) than lung cancer patients without CPFE.
Conclusions: This meta-analysis demonstrated that lung cancer patients with CPFE have more aggressive clinical characteristic and a poor prognosis, suggesting that lung cancer patients with CPFE should be early detected, treated reasonably and be taken good care of.
Methods: The databases PubMed, Embase, and Web of Science (updated to October 1, 2017) were searched for eligible studies. Pooled odds ratios (ORs), weighted mean differences (WMD) or hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to evaluate the clinicopathological characteristics, the short-term outcome after operation and long-term survival of lung cancer patients with CPFE compared with lung cancer patients without CPFE (fibrosis, emphysema, and normal).
Results: Thirty original studies with 8,050 patients were included in this meta-analysis. The pooled results indicated that lung cancer patients with CPFE were associated with higher age (MD =3.39; 95% CI: 2.12–4.67, P<0.001), male (OR =8.46; 95% CI: 6.36–11.26, P<0.001), ex- or current smoker (OR =39.65; 95% CI: 15.64–100.5, P<0.001), longer smoking history (MD =15.56; 95% CI: 3.73–27.39, P=0.01), lower DLCO% (MD =−13.82; 95% CI: −21.4 to −6.24, P<0.001), squamous cell carcinoma histology (OR =3.55; 95% CI: 2.49-5.05, P<0.001), the lower lobes (OR =1.92; 95% CI: 1.52–2.43, P<0.001), advanced pathological stage (OR =1.55; 95% CI: 1.22–1.96, P<0.001). Lung cancer patients with CPFE had higher 30-day mortality (OR =4.72, 95% CI: 2.06–10.85, P<0.001), 90-day mortality (OR =5.33; 95% CI: 1.39–20.42, P=0.01), and incidence of postoperative complications (OR =5.25, 95% CI: 2.38–11.57, P<0.001). In addition, the lung cancer patients with CPFE had a poorer OS (HR =2.006, 95% CI: 1.347–2.986, P=0.001) than lung cancer patients without CPFE.
Conclusions: This meta-analysis demonstrated that lung cancer patients with CPFE have more aggressive clinical characteristic and a poor prognosis, suggesting that lung cancer patients with CPFE should be early detected, treated reasonably and be taken good care of.
